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Abstract: 2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is utilized in the formulation of pharmaceutical
products and recently orphan designation was granted for the treatment of Niemann–Pick disease, type
C. The exact mechanism of HPBCD action and side effects are not completely explained. We used
fluorescently labelled hydroxypropyl-beta-cyclodextrin (FITC-HPBCD) to study its pharmacokinetic
parameters in mice and compare with native HPBCD data. We found that FITC-HPBCD has fast
distribution and elimination, similar to HPBCD. Interestingly animals could be divided into two
groups, where the pharmacokinetic parameters followed or did not follow the two-compartment,
first-order kinetic model. Tissue distribution studies revealed, that a significant amount of
FITC-HPBCD could be detected in kidneys after 60 min treatment, due to its renal excretion.
Ex vivo fluorescent imaging showed that fluorescence could be measured in lung, liver, brain and
spleen after 30 min of treatment. To model the interaction and cellular distribution of FITC-HPBCD
in the wall of blood vessels, we treated human umbilical vein endothelial cells (HUVECs) with
FITC-HPBCD and demonstrated for the first time that this compound could be detected in the
cytoplasm in small vesicles after 30 min of treatment. FITC-HPBCD has similar pharmacokinetic to
HPBCD and can provide new information to the detailed mechanism of action of HPBCD.
Keywords: hydroxypropyl-beta-cyclodextrin; pharmacokinetics; HUVECs; endocytosis; fluorescence
1. Introduction
2-Hydroxypropyl-beta-cyclodextrin (HPBCD) is widely utilized as pharmaceutical excipient in
several products. On the other hand, orphan designation (EU/3/11/895) was granted by the European
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Commission for hydroxy-propyl-beta-cyclodextrin for the treatment of Niemann–Pick disease, type C
(NPC) in 2011 [1]. Between 2013 and 2015, a non-randomized, open-label, phase 1–2 trial was conducted
to establish the safety and efficacy of lumbar intrathecal HPBCD in patients with NPC1 [2]. The
result of the study showed, that HPBCD slowed disease progression with an acceptable safety profile.
Indeed, HPBCD is listed in the Food and Drug Administration’s (FDA) list of inactive pharmaceutical
ingredients [3] and a previous publication showed, that intravenously (i.v.) administration of HPBCD
is safe and well tolerated [4,5]. HPBCD is always a mixture of isomers with various degrees of
substitution (DS), which may influence the complexation ability of the cyclodextrins [6]. We also tested
the cytotoxicity and hemolytic activity of HPBCD with different DS and found no toxicity on Caco-2
cells and low hemolytic activity [6,7]. Pharmacokinetic studies of i.v. HPBCD revealed fast elimination
and distribution over the extracellular fluid. I.v. HPBCD is eliminated by glomerular filtration from the
blood and had only reversible vacuolation in kidneys but did not cause kidney dysfunction in animals
or humans [4,5]. However, earlier studies reported that subcutaneous long-term administration of
HPBCD at a daily dose of 200 mg/kg caused bone loss in rats [8], 2 week 0.25–0.5 g/kg/infusion of
HPBCD caused inflammatory changes in the lung of treated pigs [9] and foamy macrophage infiltration
of the lung after 4–7 days 225 mg/kg/day i.v. in rats [4]. Ototoxicity is another reported risk [10],
which was found in cats [11] mice [12,13] and in humans [2], but the mechanism of ototoxicity is
unknown [10]. It was also revealed using fluorescent cyclodextrin derivatives, that HPBCD (and other
cyclodextrins) is able to enter the cytoplasm of different cell types by endocytosis [14–18]. This process
can be essential for the effects of HPBCD. The pharmacokinetic of native HPBCD after different routes
of administration was characterized in animal models and in humans [19,20], but to discover the exact
mechanism of action at the level of tissues and cells, sensitive methods are required. Radiolabeling of
cyclodextrins [21] and covalent conjugation of fluorophores to the cyclodextrin ring are possible tools
for detection [22]. Fluorescent HPBCD derivatives can be applied to study the behavior of HPBCD
at the level of tissues and cells and may help to understand its effects and side effects. We aimed to
reveal the pharmacokinetic parameters and tissue distribution of FITC-HPBCD in mice, administered
intravenously and compare the data of HPBCD available in the literature. We also investigated the
interaction of FITC-HPBCD with human endothelial cells, which constitute the first barrier in the body
after i.v. administration of drugs.
2. Materials and Methods
2.1. Materials
6-deoxy-6-[(5/6)-fluoresceinylthioureido]-(2-hydroxypropyl)-β-cyclodextrin (FITC-HPBCD) was
synthesized on the analogy of rhodaminyl HPBCD as described earlier [23]. FITC-HPBCD was the
product of Cyclolab Ltd. (Budapest, Hungary). FITC-HPBCD product number: CY-F-2005.1, average
degree of substitution (DS) determined by NMR were DS = 0.7 for FITC and DS = 4.1 for hydroxypropyl
groups. FITC-HPBCD was purified by extensive dialization to remove impurities. Free dye and
6-deoxy-6-monoamino-HPBCD contents were tested by capillary electrophoresis (CE) and were below
the limit of detection. All other reagents were from Sigma-Aldrich (Budapest, Hungary).
2.2. Cell Culture
Human umbilical vein endothelial cells (HUVECs) were removed from umbilical veins by exposure
to dispase (0.2% in Hank’s balanced salt solution) and cultured in gelatin-coated flasks in medium 199
containing 15% foetal bovine serum (FBS), antibiotics, L-glutamine, sodium pyruvate and endothelial
cell growth supplement from bovine pituitary [24]. For the fluorescent microscopic experiments, cells
were seeded onto gelatin-coated round glass coverslips and maintained in medium until the treatments.
Biomolecules 2019, 9, 509 3 of 13
2.3. Intracellular FITC-HPBCD Accumulation in HUVEC Cells
2.3.1. Fluorescence Microscopy
HUVECs, cultured on gelatin-coated glass coverslips were washed twice with Hank’s Balanced
Salt Solution (HBSS) and treated with 50 µM FITC-HPBCD for 30 min at 37 ◦C. Cells were washed
five times with ice-cold HBSS and fixed with 3% paraformaldehyde for 15 min. After fixation cells
were washed with HBSS and the nuclei were stained with Hoechst 33,342 at the final concentration of
300 nM. Cells were washed again and mounted on microscope slides. Samples were observed with
a Zeiss Axio Scope.A1 fluorescence microscope (HBO 100 lamp) (Carl Zeiss Microimaging GmbH,
Göttingen, Germany). Images were analyzed with ZEN 2012 v.1.1.0.0. software (Carl Zeiss Microscopy
GmbH, Göttingen, Germany)
2.3.2. Flow Cytometry
In the flow cytometry experiments, HUVECs were treated with 50 µM FITC-HPBCD for 30 min at
37 ◦C and washed five times with ice-cold HBSS. Half of the samples were incubated for a further 60
min in HBSS at 37 ◦C. After the above-mentioned incubations every sample was trypsinized, the cell
suspensions were washed twice with ice-cold HBSS and analyzed with a FACScan flow cytometer
(BD Biosciences, San Jose, CA, USA). Propidium-iodide (PI) (2 µg/mL) was added to the samples to
recognize dead cells and exclude them from the evaluation. FITC-HPBCD was excited by an argon
laser at 488 nm and the emission was detected via 530/30 nm band pass filter. Data were analyzed by
BDIS Cellquest software (Becton-Dickinson). The cellular fluorescence intensities of the FITC-HPBCD
treated cells were compared to the fluorescence of the untreated control cells and expressed as relative
cellular fluorescence intensities.
2.4. In Vivo Pharmacokinetic Investigation
Twelve BALB/c male mice (23–25 g) were involved in the study. 0.25 mg FITC-HPBCD, dissolved
in 0.2 mL saline solution was injected into the lateral tail vein of each mouse. Blood samples were
collected from the orbital sinus from six mice after 1, 15, 30 and 60 min and at 1, 15, 45 and 60 min
from other six mice by the same sampling method. Blood samples were incubated for 1 h at 37 ◦C and
centrifuged for 8 min at 1700 rpm to separate blood plasma. Aliquots of plasma from the samples
were placed into black 96-well plates and their fluorescence intensities were measured by a FLUOstar
Optima microplate reader (BMG LABTECH, Offenburg, Germany; 492 nm excitation and 520 nm
emission wavelengths) and the plasma FITC-HPBCD concentrations were calculated. Using these
data, the main pharmacokinetic parameters were determined: rate constants of elimination (ke) and
compartmentalization (kc), volume of distribution (Vd), clearance (CL) and half-life (t1/2):
t1/2 =
ln(2)
ke
(1)
CL = ke × Vd (2)
The two compartment model was characterized by the following equations:
Ct = C′ × e−kc×t + C′′ × e−ke×t (3)
C0 = C′ + C′′ (4)
where ke is the elimination rate constant of FITC-HPBCD determined from data of the terminal phase
(ke(30-60 min) or ke(45-60 min)); t1/2 is the half-life of FITC-HPBCD calculated from the corresponding
ke values; CL is the clearance of FITC-HPBCD; Vd is the volume of distribution of FITC-HPBCD
determined from data related to the first minute (Vd1); Ct is the plasma concentration of FITC-HPBCD at
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“t”; C′ and C” are the two components of the initial plasma concentration of FITC-HPBCD representing
the amount of FITC-HPBCD that will be compartmentalized and eliminated, respectively.
After the last blood sample collection, six animals were anaesthetized, and their blood vessels
were perfused by warm saline solution. Finally, all mice were sacrificed, and the organs were removed
from the six saline-perfused mice for further analysis. The collected organs (livers, lungs, kidneys,
spleens, hearts and brains) were homogenized by adding 0.8 mL saline solution and the homogenates
were centrifuged at 10,000 rpm for 20 min at 4 ◦C. From each sample, 0.1 mL of supernatant was
placed into black 96-well plates and the fluorescence intensities were measured by microplate reader
as described above. The lower limit of quantification of FITC-HPBCD in mouse plasma and organ
homogenates was 0.25 µg/mL. The protein content of the tissue samples was determined by PierceTM
BCA protein assay (Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instruction.
FITC-HPBCD content of the samples was normalized to the tissue protein content. The animals were
maintained in accordance with the Guidelines for the Care and Use of Laboratory Animals; experiments
were approved by the Animal Care Committee of the University of Debrecen (permission no. 12/2014).
2.5. In Vivo Fluorescence Imaging Experiments
Male BALB/c mice (22–25 g) were bred and maintained in normal watering and feeding conditions
in a Laboratory Animal Husbandry Facility, equipped with IVC (individually ventilated cages),
controlled atmosphere-temperature, humidity and lighting (Vasile Goldis Western University, Arad,
Romania). All experimental procedures were performed in compliance with the appropriate laws and
institutional guidelines, and were approved by the Institutional Ethics Committee of Vasile Goldis,
Western University of Arad (Arad, Romania). FITC-HPBCD (0.5 and 2.5 mg), dissolved in 0.1 mL
saline solution was injected into the femoral vein of mice under general anaesthesia. Maintaining
the surgical plane of anesthesia, mice were placed into an in vivo imaging system (In-vivo Xtreme,
Carestream, Carestream Health Inc. USA). At 5, 15, 30, 45 and 60 min, fluorescence and X-ray images
were recorded of the animals. After 30 or 60 min, the blood vessels of some animals were perfused by
warm saline solution and their organs (livers, lungs, kidneys, spleens and brains) were removed for ex
vivo imaging (excitation: 480 nm, emission: 535 nm).
2.6. Statistical Analysis
SigmaStat software (version 3.1, SPSS Inc.) was used for statistical analysis. Data are expressed as
means ± SD. Comparison of groups was perfomed by ANOVA. Differences were considered significant
at p < 0.05.
3. Results
3.1. In Vivo Pharmacokinetic Investigation
At first, our aim was to find the best model for the pharmacokinetics of FITC-HPBCD and
determine its pharmacokinetic parameters. We applied two experimental protocols. In the first case,
we took blood samples from the animals at 1, 15, 30 and 60 min, and in the second case, at 1, 15, 45 and
60 min. When data of FITC-HPBCD were evaluated, the two-compartment model with the assumption
of first-order elimination kinetics showed the best fit. During the calculation of the rate constants of
elimination (ke) and compartmentalization (kc), we identified two distinct groups of animals. In the
first group (Group F), a kc value greater than ke could be computed (so, the behavior of FITC-HPBCD
in the animals of Group F was consistent with expectations resulted from the two-compartment,
first-order kinetic model) (Table 1 and Figure 1A,C). However, in the second group (Group NF), kc
could not be determined (thus, the fate of FITC-HPBCD did not follow expectations of our model)
(Table 1 and Figure 1B,D). Interestingly, both groups contained six mice, irrespectively of the sampling
protocol used.
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Table 1. Pharmacokinetic parameters of 6-deoxy-6-[(5/6)-fluoresceinylthioureido]-(2-hydroxypropyl)-β-
cyclodextrin (FITC-HPBCD), administered intravenously to mice.
Group F Group NF Group F Group NF
Dose (µg) 250 250 Dose (µg) 250 250
t1/2 (1–15 min) 7.82 ± 1.48 6.13 ± 0.78 t1/2 (1–15 min) 7.5 ± 1.13 6.50 ± 0.31
t1/2 (15–30 min) 7.54 ± 0.52 35.01 ± 10.15 t1/2 (15–45 min) 13.55 ± 1.45 13.36 ± 3.05
t1/2 (30–60 min) 122.3 ± 109.4 16.61 ± 7.12 t1/2 (45–60 min) 20.06 ± 3.89 8.99 ± 4.54
ke (1–15 min) 0.092 ± 0.023 0.115 ± 0.017 ke (1–15 min) 0.095 ± 0.017 0.107 ± 0.006
ke (15–30 min) 0.092 ± 0.007 0.022 ± 0.009 ke (15–45 min) 0.052 ± 0.007 0.054 ± 0.013
ke (30–60 min) 0.022 ± 0.029 0.049 ± 0.020 ke (45–60 min) 0.036 ± 0.008 0.095 ± 0.044
kc (1–15 min) 0.109 ± 0.026 nd kc (1–15 min) 0.142 ± 0.033 nd
Vd (mL) 4.86 ± 0.21 4.70 ± 1.27 Vd (mL) 6.25 ± 0.77 7.01 ± 0.81
CL (mL/min) 0.11 ± 0.15 0.25 ± 0.15 CL (mL/min) 0.23 ± 0.08 0.69 ± 0.38
Group F: pharmacokinetic parameters followed the two-compartment, first-order kinetic model. Group NF:
pharmacokinetic parameters did not follow the two-compartment, first-order kinetic model. Vd: Volume of
distribution at 1 min. CL: clearance. nd: kc values in Group NF could not be determined.
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Figure 1. Plasma concentration curves of FITC-HPBCD after i.v. administration in mice. Sampling 
times 1, 15, 30 and 60 min (A and B; n = 6) and 1, 15, 45 and 60 min (C and D; n = 6). A and C followed 
the first-order elimination kinetic, while B and D did not follow it. 
FITC-HPBCD showed fast elimination in mice after i.v. administration. Within 60 min 96.58 ± 
2.6% (n = 12) of the i.v. administered FITC-HPBCD was eliminated from mice. Despite the fast 
elimination, FITC-HPBCD showed rapid compartmentalization (confirmed by the calculation of 
volume of distribution: Vd). Vd was higher than the blood volume of mice, at the first minute, it was 
5.7 ± 1.34 mL (n = 12). There was no significant difference between Vd values of the two groups with 
different elimination parameters. Compartmentalization and elimination of the compound in 
question happened at the same time in the animals, but in the group not following the kinetic model, 
distribution appeared to be too complex for a simple interpretation. 
After 60 min of the pharmacokinetic experiment, we analyzed the tissue accumulation of FITC-
HPBCD in tissue homogenates ex vivo. The fluorescence intensities of FITC-HPBCD in the 
supernatant of liver, lung, spleen, heart and brain homogenates were not elevated after 60 min of the 
experiment. Only the homogenates of kidneys showed significant fluorescence (Figure 2). 
Figure 1. Plasma concentration curves of FITC-HPBCD after i.v. administration in mice. Sampling
times 1, 15, 30 and 60 min (A and B; n = 6) and 1, 15, 45 and 60 min (C and D; n = 6). A and C followed
the first-order elimination kinetic, while B and D did not follow it.
FITC-HPBCD showed fast elimination in mice after i.v. administration. Within 60 min
96.58 ± 2.6% (n = 12) of the i.v. administered FITC-HPBCD was eliminated from mice. Despite
the fast elimination, FITC-HPBCD showed rapid compartmentalization (confirmed by the calculation
of volume of distribution: Vd). Vd was higher than the blood volume of mice, at the first minute, it
was 5.7 ± 1.34 mL (n = 12). There was no significant difference between Vd values of the two groups
with different elimination parameters. Compartmentalization and elimination of the compound in
question happened at the same time in the animals, but in the group not following the kinetic model,
distribution appeared to be too complex for a simple interpretation.
After 60 min of the pharmacokinetic experiment, we analyzed the tissue accumulation of
FITC-HPBCD in tissue homogenates ex vivo. The fluorescence intensities of FITC-HPBCD in the
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supernatant of liver, lung, spleen, heart and brain homogenates were not elevated after 60 min of the
experiment. Only the homogenates of kidneys showed significant fluorescence (Figure 2).
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Two doses (0.5 mg and 2.5 mg/animal) of FITC-HPBCD were administered to the mice i.v. in the 
in vivo fluorescence imaging experiments. Images were recorded at 5, 15, 30, 45 and 60 min. In both 
cases, significant fluorescence could be observed in the animals (Figure 3, mice on the right in the 
images), compared to the control mice (Figure 3, mice on the left in the images). The compound was 
distributed over the entire body of the animals and their fluorescence intensities decreased as a 
function of time.  
Figure 2. FITC-HPBCD content in the supernatant of the tissue homogenates of mice. FITC-HPBCD
was administered i.v. and after 60 min of treatment significant fluorescence intensity could be measured
only in the supernatant of kidney homogenates (*** p < 0.001).
3.2. In Vivo Fluorescence Imaging Experiments
Two doses (0.5 mg and 2.5 mg/animal) of FITC-HPBCD were administered to the mice i.v. in the
in vivo fluorescence imaging experiments. Images were recorded at 5, 15, 30, 45 and 60 min. In both
cases, significant fluorescence could be observed in the animals (Figure 3, mice on the right in the
images), compared to the control mice (Figure 3, mice on the left in the images). The compound was
distributed over the entire body of the animals and their fluorescence intensities decreased as a function
of time.
After 30 or 60 min, animals were perfused with warm saline solution and their organs were
removed to measure the ex vivo fluorescence intensities. In case of the 2.5 mg/animal dose, every
organ showed higher fluorescence intensities (Figure 4, organs on the right) than the control samples
(Figure 4, organs on the left). Kidneys had especially high fluorescence and lung showed elevated
intensity. From the administration of 0.5 mg FITC-HPBCD, the fluorescence intensities of the removed
organs were similar to the control when imaged together, only kidneys had relative higher fluorescence
after 30 min. Separated examination of brains with different gains revealed that in both doses, the
brains of the treated animals had higher fluorescence than the untreated ones after 30 min. After
60 min there was no difference between the organelle fluorescence of the brains, the intensity of the
treated sample decreased to the control level.
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Figure 3. Representative in vivo fluorescence images of FITC-HPBCD treated mice. FITC-HPBCD (0.5 
and 2.5 mg) was injected i.v. and images were recorded at 5, 15 and 30 min after injection. Untreated 
mice can be seen on the left and FITC-HPBCD treated mice can be seen on the right in each image. 
FITC-HPBCD distributed over the entire body of mice and the in vivo fluorescence decreased as a 
function of time. 
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Figure 3. Representative in vivo fluorescence images of FITC-HPBCD treated mice. FITC-HPBCD (0.5
and 2.5 mg) was injected i.v. and images were recorded at 5, 15 and 30 min after injection. Untreated
mice can be seen on the left and FITC-HPBCD treated mice can be seen on the right in each image.
FITC-HPBCD distributed over the entire body of mice and the in vivo fluorescence decreased as a
function of time.
Interestingly, lungs also showed higher ex vivo fluorescence in separated imaging after 0.5 mg
FITC-HPBCD administration compared to the untreated control (see Supplementary Material Figure
S1). It could be observed that FITC-HPBCD accumulated in the bladder (30 and 45 min) and then was
urinated out (60 min) (see Supplementary Material Figure S2).
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5). In control cells, some autofluorescent vesicles could be identified. 
Figure 4. Representative ex vivo fluorescence images of the organs of FITC-HPBCD treated mice after
30 min treatment. Brains were examined separately from other organs after 30 and 60 min of treatment
and imaged from beneath. The organs of untreated mice can be seen on the left in the images. Kidneys
showed the highest fluorescence intensities in both doses (0.5 and 2.5 mg). In the case of 2.5 mg dose,
lung also had elevated intensity. At 30 min the brains of the FITC-HPBCD treated animals had higher
fluorescence than the controls, while after 60 min there was no difference between the fluorescence of
the brai s.
3.3. Intracellular FITC-HPBCD Accumulation in HUVEC Cells
3.3.1. Fluorescence Microscopy
FITC-HPBCD could be detected in the cytoplasm of HUVECs in small green vesicles af er 30 min
of incubation. Some larger, mor intense vesicles could be observed around the cell nuclei (Figure 5).
In control cells, some autofluorescent vesicles could be identified.
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Figure 5. Fluorescence microscopic images of FITC-HPBCD treated (A) and untreated (B) human 
umbilical vein endothelial cells (HUVECs). Endocytotic green vesicles can be observed in the 
cytoplasm (A), while some autofluorescent vesicles can be seen in the control cells (B). (Green—FITC-
HPBCD, blue—cell nuclei). 
3.3.2. Flow Cytometry 
To confirm cellular uptake of FITC-HPBCD by HUVECs, flow cytometric measurements were 
performed. After 30 min of incubation with FITC-HPBCD and extensive washing of cells, the cellular 
fluorescence was quantified by flow cytometer. FITC-HPBCD treatment significantly increased the 
cellular fluorescence, compared to the untreated control. Incubation of cells for 60 min in HBSS after 
30 min of FITC-HPBCD treatment significantly decreased the fluorescence of HUVECs (Figure 6). 
 
Figure 6. Flow cytometric analysis of FITC-HPBCD uptake in HUVECs. Incubation of HUVECs for 
30 min with 50 µM of FITC-HPBCD significantly increased the cellular fluorescence and a following 
Figure 5. Fluorescence microscopic images of FITC-HPBCD treated (A) and untreated (B) human
umbilical vein endothelial cells (HUVECs). Endocytotic green vesicles can be observed in the cytoplasm
(A), while some autofluorescent vesicles can be seen in the control cells (B). (Green—FITC-HPBCD,
blue—cell nuclei).
3.3.2. Flow Cytometry
To confirm cellular uptake of FITC-HPBCD by HUVECs, flow cytometric measurements were
performed. After 30 min of incubation with FITC-HPBCD and extensive washing of cells, the cellular
fluorescence was quantified by flow cytometer. FITC-HPBCD treatment significantly increas d the
cellular fluorescence, compared to the untrea d control. Incubation of cells for 60 min HBSS af er
30 min of FITC-HPBCD treatment significantly ecreased the fluorescence of HUVECs (Figure 6).
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Figure 6. Flow cytometric analysis of FITC-HPBCD uptake in HUVECs. Incubation of HUVECs for
30 min with 50 µM of FITC-HPBCD significantly increased the cellular fluorescence and a following
60 min washing with HBSS decreased it. (Data are xpressed as means ±SD, n = 3, significance is
expressed as **p < 0.01).
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4. Discussion
In recent years, much attention was paid to the pharmacological and toxicological effects
of cyclodextrins, especially to HPBCD. HPBCD is widely used excipient in oral and parenteral
formulations, furthermore it is applied as orphan drug in the treatment of Niemann–Pick disease,
type C. The pharmacokinetic properties of HPBCD was studied in rats [19] and humans [2,5,25], but
the tissue distribution and the interactions with organs of this compound was moderately revealed.
Mainly the nephrotoxicity was considered. It is known that HPBCD has extracellular distribution
and fast elimination by glomelural filtration. FITC-HPBCD provides an excellent tool to study the
above-mentioned questions and the molecule can also be detected sensitively at a cellular level. Moreover,
FITC-HPBCD was successfully used to monitor renal functions [26]. In our experiments, FITC-HPBCD
was administered to mice i.v. and blood samples were collected according to two protocols. At first,
blood samples were collected at 1, 15, 30 and 60 min from six mice. Then the experiments were repeated
by applying 1, 15, 45 and 60 min sampling times with six other animals and the pharmacokinetic
parameters of mice varied in a relatively narrow range (Table 1). The t1/2 and ke values calculated from
data belonging to different time periods were different, thus they showed, that FITC-HPBCD had no
simple elimination. As FITC-HPBCD was administered i.v., the most likely reason of the variation of ke
values was the presence of more than one compartment for FITC-HPBCD. ke values decreasing over
time are well fitted to the characteristics of a two-compartment model. Among the presented ke values,
the ke belonging to the terminal phase (ke (30–60 min) or ke (45–60 min)) was considered to be closest to the
truth. Thus, this ke value was used for the calculation of CL, as CL also characterizes the elimination.
On the other hand, FITC-HPBCD was eliminated rapidly into the urine, and Vd was the least biased by
elimination at the first minute (Vd1), because at the beginning of the process compartmentalization was
more significant. As a result, ke (30–60 min) or ke (45–60 min) and Vd1 were used for the calculation of CL. kc
was also calculated from data at the first time period (kc (1–15 min)).
The data evaluation revealed that the animals could be divided into two groups, where the
pharmacokinetic parameters followed or did not follow the two-compartment model. Interestingly, the
number of the animals in the group following the model was the same as in the group not following
the model. The difference between the two groups was in the ke values. In the group not following the
model the ke was higher than kc. The reason of this phenomenon is not known, but the distribution
seems to be too complex. Nephrotoxicity can be excluded as a possible reason, because it decreases
glomerular filtration and elimination rate [19]. The applied dose was approximately 10 mg/kg, lower
than used earlier in rats [19] and this dose is much below the no observed adverse effect levels
(NOAELs) of HPBCD in rats (50 mg/kg/day) [4,27]. Pharmacokinetic data revealed that FITC-HPBCD
had fast elimination in mice, similar to HPBCD data in rats and humans. The t1/2 of FITC-HPBCD was
between 6–8 min in the first 15 min and 9–20 min in the 30–60 or 45–60 min sampling period. Only two
animals (belonging to the group following the model) had high t1/2, causing big deviation. The group
not following the model had lower t1/2 in the last period. Vd values showed fast distribution, at 1 min
these were between 4.7 and 7 mL, which were higher than the expected blood volume of mice. The two
groups had similar Vd at 1 min of sampling, it was 5.55 ± 0.98 mL (n = 6) for the group following the
model, and 5.85 ± 1.72 (n = 6) for the group not following the model (Table 1). It should be noted that
the average Vd was 5.7 ± 1.34 mL (n = 12), which corresponds well with the extracellular fluid volume
(5.8 ± 0.3 mL for 28.6 ± 1.2 g male mice) determined in wild-type C57BL6 mice [28]. According to these
data, FITC-HPBCD rapidly distributes over the extracellular fluid after i.v. administration.
Measurement of the tissue distribution of FITC-HPBCD after 60 min of treatment showed that
tissue accumulation could be detected only in kidneys. The major route of elimination of HPBCD is
renal excretion and similar to earlier studies on rats with HPBCD, the target organs of FITC-HPBCD
are kidneys in mice. Ex vivo fluorescence studies showed more details of distribution. After 30 min of
treatment, significant fluorescence could be also detected in other organs like lung, liver and brain.
It is in agreement with earlier findings, where the highest HPBCD concentrations were found in
kidneys and lung of rats and in kidneys and liver of dogs [4]. Recently, we also found relatively higher
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68Ga-NODAGA-HPBCD activity in the lung after 30 min compared to other organs [21]. Interestingly,
we found FITC-HPBCD fluorescence in the brain after 30 min, which decreased to the control level at
60 min in accordance with the tissue distribution result. In experiments carried out with [14C]-HPBCD
on wild type BALB/c (Npc1+/+) mice and Npc1−/−mice, it was found that the Vd at 2 min available to
HPBCD exceeded the plasma and vascular volume of the brain, indicating a significant binding of
HPBCD to the brain vasculature without crossing of the blood–brain barrier (BBB) [29]. The interaction
of FITC-HPBCD and endothelial cells can explain the fluorescence of the brain, without BBB penetration.
The molecular structure, hydrophilicity and high molecular weight predict that cyclodextrins do not
penetrate biological membranes [30]. However, we recently showed that fluorescent cyclodextrins are
able to enter Caco-2 intestinal epithelial cells by endocytosis [14,15]. To test the possible interactions of
FITC-HPBCD with endothelial cells we treated HUVECs with this compound and investigated the
cellular fluorescence. We found for the first time, that FITC-HPBCD localized in the cytoplasm of
HUVECs in small endocytic vesicles after 30 min treatment. On the fluorescence microscopic images,
numerous small vesicles can be observed in the cytoplasm of the treated cells. Interestingly, some
autofluorescent vesicles can also be seen in the control cells. The autofluorescence of HUVECs was
reported by other studies, but its origin is unknown [31]. The internalization and increase of cellular
fluorescence were confirmed by flow cytometry. After 60 min incubation of FITC-HPBCD loaded
cells with HBSS, the fluorescence was markedly decreased, but not completely. This indicates that
endothelial cells can take part in the distribution of FITC-HPBCD in the body, but on the other hand,
the endocytosis of FITC-HPBCD should be confirmed by other types of endothelial cells, like brain
capillary endothelial cells.
Limitations of the study: The in vivo fluorescence imaging experiments were not suitable to
detect the real-time organ distribution of FITC-HPBCD in mice. FITC-HPBCD in the highly perfused
skin capillaries gives a strong fluorescence signal from the skin of the animals, obscuring the signal
of the organs from the deeper layer. Ex vivo organ measurements were needed to reveal the organ
distribution of FITC-HPBCD.
5. Conclusions
In conclusion FITC-HPBCD has similar pharmacokinetic properties to HPBCD, although we
found some deviation from the applied two-compartment model. It should be noted that we tested
this molecule on mice, while the available data originates from other species. The fast elimination,
similar t1/2, Vd and tissue distribution show that FITC-HPBCD could be a suitable alternative model
molecule to study and understand the pharmacological effect of HPBCD. The higher distribution
in the lung can explain the pulmonary side effects of HPBCD, but on the other hand it may help
to develop new targeting strategies. The great advantage of FITC-HPBCD is the easy, simple and
sensitive detection, compared to HPBCD. The applied fluorescent technology can also help to test
new cyclodextrin derivatives for targeted therapy. In addition, further studies are needed to test other
administration routes.
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